Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Variant||KMT2A - MLLT1|
|Protein Effect||gain of function|
|Gene Variant Descriptions||KMT2A-MLLT1 (also referred to as MLL-ENL) results from the fusion of KMT2A and MLLT1, resulting in transformation in culture and leukemogenesis in mouse models (PMID: 9250666). KMT2A-MLLT1 has been identified in acute myeloid leukemia (PMID: 33020282), T-lymphoblastic leukemia/lymphoma (PMID: 30203571), and acute lymphoblastic lymphoma (PMID: 34966090)|
|Associated Drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KMT2A - MLLT1||acute myeloid leukemia||sensitive||MI-503||Preclinical - Cell culture||Actionable||In a preclinical study, MI-503 inhibited growth of an acute myeloid leukemia cell line harboring KMT2A-MLLT1 (MLL-ENL) in culture (PMID: 25817203).||25817203|
|KMT2A - MLLT1||acute lymphoblastic leukemia||predicted - sensitive||I-BET151 + Prednisolone||Preclinical - Cell culture||Actionable||In a preclinical study, treatment with I-BET151 enhanced the efficacy of Omnipred (prednisolone) in acute lymphoblastic leukemia cells harboring a KMT2A-MLLT1 (also known as MLL-ENL) fusion, resulting in increased cell death compared to either therapy alone in culture (PMID: 29748211).||29748211|
|KMT2A - MLLT1 NRAS G12D||acute myeloid leukemia||predicted - sensitive||AZD0156||Preclinical||Actionable||In a preclinical study, AZD0156 treatment resulted in growth inhibition of tumor cells and prolonged survival in animal models of acute myeloid leukemia harboring KMT2A-MLLT1 fusion and NRAS G12D (PMID: 27625305).||27625305|
|KMT2A - MLLT1 NRAS G12D||acute myeloid leukemia||sensitive||Dinaciclib||Preclinical||Actionable||In a preclinical study, acute myeloid leukemia cells co-harboring KMT2A-MLLT1 and NRAS G12D demonstrated a decrease in tumor burden, reduced colony formation, and an increase in cell death when treated with Dinaciclib in both culture and mouse models (PMID: 26627013).||26627013|
|KMT2A - MLLT1 NRAS G12D||acute myeloid leukemia||predicted - sensitive||AZ20||Preclinical||Actionable||In a preclinical study, AZ20 treatment resulted in growth inhibition of tumor cells and prolonged survival in animal models of acute myeloid leukemia harboring KMT2A-MLLT1 fusion and NRAS G12D (PMID: 27625305).||27625305|